1. MedicineNet. Definition of heart failure, available from http://www.medterms.com/ script/main/art.asp?articlekey=3672. 2016.
2. Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, et al: Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011, 123:933-944.
3. Liu LC, Damman K, Lipsic E, Maass AH, Rienstra M, Westenbrink BD: Heart failure highlights in 2012–2013. European journal of heart failure 2014, 16:122-132.
4. Stewart S, MacIntyre K, Capewell S, McMurray J: Heart failure and the aging population: an increasing burden in the 21st century? Heart 2003, 89:49-53.
5. Rathi S, Deedwania PC: The epidemiology and pathophysiology of heart failure. Medical Clinics 2012, 96:881-890.
6. Conditions NCCfC: Chronic Heart Failure: national clinical guideline for diagnosis and management in primary and secondary care. In. Royal College of Physicians; 2003
7. Sadeghi M, Haghdoost AA, Bahrampour A, Dehghani M: Modeling the burden of cardiovascular diseases in Iran from 2005 to 2025: The impact of demographic changes. Iranian journal of public health 2017, 46:506.
8. Forouzanfar MH, Sepanlou SG, Shahraz S, BESc PN, Pourmalek F, Lozano R, et al: Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Archives of Iranian medicine 2014, 17:304.
9. Hatmi Z, Tahvildari S, Motlag AG, Kashani AS: Prevalence of coronary artery disease risk factors in Iran: a population based survey. BMC cardiovascular disorders 2007, 7:32.
10. Fakhrzadeh H, Bandarian F, Adibi H, Samavat T, Malekafzali H, Hodjatzadeh E, et al: Coronary heart disease and associated risk factors in Qazvin: a population-based study. EMHJ-Eastern Mediterranean Health Journal, 14 (1), 33-41, 2008 2008, 14:33-41.
11. Naghavi M: Features of death in 18 province of Iran in 2000. Tehran: Tandis Publications 2002.
12. Felker GM, Hasselblad V, Hernandez AF, O'Connor CM: Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. American heart journal 2009, 158:422-430.
13. Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H: B-type natriuretic peptide–guided heart failure therapy: a meta-analysis. Archives of Internal Medicine 2010, 170:507-514.
14. Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T: Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 2009, 95:1508-1513.
15. Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al: BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. Jama 2009, 301:383-392.
16. Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, et al: N-terminal pro–B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP–Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. Journal of the American College of Cardiology 2009, 55:53-60.
17. Laramée P, Wonderling D, Swain S, Al-Mohammad A, Mant J: Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. Heart 2013, 99:267-271.
18. Pufulete M, Maishman R, Dabner L, Higgins JP, Rogers CA, Dayer M, et al: B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data. Systematic reviews 2018, 7:112.
19. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al: 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013, 62:e147-e239.
20. Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J, et al: Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ open 2016, 6:e014010.
21. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW: Methods for the economic evaluation of health care programmes. Oxford university press; 2005.
22. Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S: Applied methods of cost-effectiveness analysis in healthcare. Oxford University Press; 2011.
23. Jafari A, Rezapour A, Hajahmadi M: Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart failure reviews 2018, 23:693-700.
24. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G: Cost effectiveness of carvedilol for heart failure. The American journal of cardiology 1999, 83:890-896.
25. Daneshmand A, Jahangard E, Abdollah-Milani M: A time preference measure of the social discount rate for Iran. Journal of Economic Structures 2018, 7:29.
26. Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian M-A, Henry D, et al: Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. DARU Journal of Pharmaceutical Sciences 2013, 21:50.
27. Göhler A, Conrads‐Frank A, Worrell SS, Geisler BP, Halpern EF, Dietz R, et al: Decision‐analytic evaluation of the clinical effectiveness and cost‐effectiveness of management programmes in chronic heart failure. European journal of heart failure 2008, 10:1026-1032.
28. Goudarzi R, Zeraati H, Sari AA, Rashidian A, Mohammad K: Population-based preference weights for the EQ-5D health states using the visual analogue scale (VAS) in Iran. Iranian Red Crescent Medical Journal 2016, 18:1-9.
29. http://apps.who.int/gho/data/?theme=main&vid=60760. .
30. Nixon RM, Wonderling D, Grieve RD: Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared. Health economics 2010, 19:316-333.
31. Limwattananon S: Handling uncertainty of the economic evaluation result: sensitivity analysis. Journal of the Medical Association of Thailand 2011, 91:59.
32. Hutubessy R, Chisholm D, Edejer TT-T: Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost effectiveness and resource allocation 2003, 1:8.
33. Moertl D, Steiner S, Coyle D, Berger R: Cost-utility analysis of NT-proBNP-guided multidisciplinary care in chronic heart failure. International journal of technology assessment in health care 2013, 29:3-11.
34. Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T: Is B-type natriuretic peptide-guided heart failure management cost-effective? International journal of cardiology 2004, 96:177-181.
35. Siebert U, Januzzi Jr JL, Beinfeld MT, Cameron R, Gazelle GS: Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. The American journal of cardiology 2006, 98:800-805.
36. Pufulete M, Maishman R, Dabner L, Mohiuddin S, Hollingworth W, Rogers CA, et al: Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. Health technology assessment 2017, 21:1-150.